Last edition
News about "Zydus Lifesciences"
Zydus Lifesciences Inks Exclusive Deal with Myriad Genetics for Cancer Risk Tests in India
Zydus Lifesciences has entered into an exclusive agreement with US-based Myriad Genetics to introduce clinically validated cancer-risk assessment diagnostic tests in India, aimed at enabling personalised, evidence-based cancer care and strengthening early detection and preventive oncology efforts in the country.
Zydus Lifesciences | 19/12/2025 | By News Bureau
Zydus and SIG Sign Deal to Launch Single-Serve Spouted Pouches for Cough and Cold Medication
Zydus Lifesciences is introducing Deriphyllin CoughGo in single-serve spouted pouches utilising SIG’s advanced filling technology.
Zydus Lifesciences | 18/11/2025 | By Dineshwori | 136
Zydus Lifesciences Secures US FDA Approval for Leuprolide Acetate Injection
Zydus Lifesciences has received final approval from the US Food and Drug Administration (FDA) for its generic version of Leuprolide Acetate injection, in a 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial format.
Zydus Lifesciences | 17/11/2025 | By Darshana | 114
Zydus Receives Final Approval from USFDA for Leuprolide Acetate Injection
Zydus has secured final USFDA approval for its Leuprolide Acetate injection, a multiple-dose formulation indicated for the palliative treatment of advanced prostate cancer.
Zydus Lifesciences | 15/11/2025 | By Dineshwori
Zydus Lifesciences Receives USFDA Tentative Nod for Generic Multiple Sclerosis Drug
Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) for Diroximel Fumarate delayed-release capsules, 231 mg, a generic version of Vumerity delayed-release capsules of the same strength.
Zydus Lifesciences | 13/11/2025 | By Dineshwori | 243
Zydus Lifesciences reported a robust performance for the second quarter ended September 30, 2025, with net profit rising over 38 percent to INR 1,258.6 crore, compared to INR 911.2 crore in the same quarter last year.
Zydus Lifesciences | 06/11/2025 | By Darshana | 138
Zydus Receives USFDA Approval for Deflazacort Oral Suspension
Zydus stated that deflazacort oral suspension will be produced at Doppel, Italy.
Zydus Lifesciences | 06/10/2025 | By Dineshwori | 122
Indian Pharmaceutical Alliance Welcomes New Leadership
Dr. Sharvil Patel, Managing Director, Zydus Lifesciences, and Vice President, Indian Pharmaceutical Alliance (IPA), has been appointed President of the alliance, while Glenn Saldanha, Chairman and Managing Director, Glenmark, will serve as the new Vice President.
Zydus Lifesciences | 04/10/2025 | By Dineshwori | 139
ICMR Licenses Nine Health Tech Innovations at India MedTech Expo 2025
At the India MedTech Expo 2025 in Delhi, ICMR licensed nine breakthrough technologies to industry partners under its Patent Mitra initiative, sealing 17 deals in diagnostics and vaccine development to advance affordable, homegrown healthcare.
Zydus Lifesciences | 05/09/2025 | By Dineshwori | 194
Zydus and Synthon Sign Exclusive Licensing and Supply Agreement for Ozanimod Capsules for US Market
Zydus Lifesciences’ subsidiary Zydus Lifesciences Global FZE has signed an exclusive licensing and supply deal with Synthon BV to commercialise generic Ozanimod Capsules (ZEPOSIA) in the US market.
Zydus Lifesciences | 05/09/2025 | By Mrinmoy Dey | 119
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy